Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Circulating Tumor DNA
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
33%
Rituximab
25%
DNA Sequence
16%
Polatuzumab Vedotin
8%
Doxorubicin
8%
Decision Making
8%
Prednisone
8%
Somatic Mutation
8%
Next Generation Sequencing
8%
Cyclophosphamide
8%
Biopsy Technique
8%
Vincristine
8%
Malignant Neoplasm
8%
Pharmacology, Toxicology and Pharmaceutical Science
Diffuse Large B Cell Lymphoma
100%
Circulating Tumor DNA
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
33%
Rituximab
25%
Chemotherapy
16%
Polatuzumab Vedotin
8%
Malignant Neoplasm
8%
Vincristine
8%
Cyclophosphamide
8%
Doxorubicin
8%
Remission
8%
Prednisone
8%
Immunology and Microbiology
B Cell
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
33%
Rituximab
25%
DNA Sequence
16%
Polatuzumab Vedotin
8%
Decision Making
8%
Somatic Mutation
8%
Cyclophosphamide
8%
Next Generation Sequencing
8%
Prednisone
8%